CN104271557B - 去泛素化活性的抑制方法 - Google Patents

去泛素化活性的抑制方法 Download PDF

Info

Publication number
CN104271557B
CN104271557B CN201280062713.XA CN201280062713A CN104271557B CN 104271557 B CN104271557 B CN 104271557B CN 201280062713 A CN201280062713 A CN 201280062713A CN 104271557 B CN104271557 B CN 104271557B
Authority
CN
China
Prior art keywords
alkyl
compound
cancer
compounds
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280062713.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104271557A (zh
Inventor
S·林德
R·拉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivolux AB
Original Assignee
Vivolux AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivolux AB filed Critical Vivolux AB
Publication of CN104271557A publication Critical patent/CN104271557A/zh
Application granted granted Critical
Publication of CN104271557B publication Critical patent/CN104271557B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201280062713.XA 2011-10-19 2012-10-15 去泛素化活性的抑制方法 Expired - Fee Related CN104271557B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1100776 2011-10-19
SE1100776-2 2011-10-19
SE1200303 2012-05-16
SE1200303-4 2012-05-16
PCT/SE2012/000158 WO2013058691A1 (en) 2011-10-19 2012-10-15 Method for inhibition of deubiquitinating activity

Publications (2)

Publication Number Publication Date
CN104271557A CN104271557A (zh) 2015-01-07
CN104271557B true CN104271557B (zh) 2017-12-05

Family

ID=48141165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280062713.XA Expired - Fee Related CN104271557B (zh) 2011-10-19 2012-10-15 去泛素化活性的抑制方法

Country Status (21)

Country Link
US (1) US9221761B2 (https=)
EP (1) EP2780326B1 (https=)
JP (1) JP6165748B2 (https=)
KR (1) KR102022575B1 (https=)
CN (1) CN104271557B (https=)
AU (1) AU2012326682B2 (https=)
BR (1) BR112014009365B1 (https=)
CA (1) CA2852518C (https=)
CL (1) CL2014000998A1 (https=)
DK (1) DK2780326T3 (https=)
EA (1) EA026409B1 (https=)
ES (1) ES2713484T3 (https=)
HU (1) HUE041816T2 (https=)
IL (1) IL232118A (https=)
MX (1) MX345467B (https=)
MY (1) MY169330A (https=)
PL (1) PL2780326T3 (https=)
PT (1) PT2780326T (https=)
SG (1) SG11201401608PA (https=)
WO (1) WO2013058691A1 (https=)
ZA (1) ZA201403302B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023236583A1 (zh) * 2022-06-07 2023-12-14 北京大学 Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401608PA (en) * 2011-10-19 2014-07-30 Vivolux Ab Method for inhibition of deubiquitinating activity
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
WO2016004221A1 (en) * 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CA2976741C (en) * 2015-03-30 2023-01-17 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
CN106146542A (zh) * 2015-04-23 2016-11-23 北京大学 姜黄素硼酸衍生物,其制备方法和应用
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
US10416163B2 (en) * 2016-02-26 2019-09-17 Regents Of The University Of Minnesota Method and treatment of recurring endometrial cancer with an inhibitor of USP14
WO2018140907A1 (en) * 2017-01-30 2018-08-02 Up Therapeutics Inc. Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
CN111956804B (zh) * 2020-07-21 2022-01-07 广州医科大学 Otub1的抑制剂的新应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
WO2007059613A1 (en) * 2005-11-22 2007-05-31 University Of Saskatchewan Antineoplastic compounds
CN101282946A (zh) * 2005-08-05 2008-10-08 海布里詹尼克斯股份公司 新的半胱氨酸蛋白酶抑制剂及它们的治疗应用
WO2011005790A1 (en) * 2009-07-06 2011-01-13 The Ohio State University Research Foundation Compositions and methods for inhibition of cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664272B2 (en) * 1999-12-03 2003-12-16 Emory University Curcumin analogs with anti-tumor and anti-angiogenic properties
EP1572078A4 (en) * 2002-03-08 2006-08-09 Univ Emory NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS
SG11201401608PA (en) * 2011-10-19 2014-07-30 Vivolux Ab Method for inhibition of deubiquitinating activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
CN101282946A (zh) * 2005-08-05 2008-10-08 海布里詹尼克斯股份公司 新的半胱氨酸蛋白酶抑制剂及它们的治疗应用
WO2007059613A1 (en) * 2005-11-22 2007-05-31 University Of Saskatchewan Antineoplastic compounds
WO2011005790A1 (en) * 2009-07-06 2011-01-13 The Ohio State University Research Foundation Compositions and methods for inhibition of cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Identification of New Compounds That Trigger Apoptosome-Independent Caspase Activation and Apoptosis;Emanuela Aleo，等;《Cancer Research》;20060915;第66卷(第18期);第9235页摘要、第9237页图1 *
Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system;Maria Berndtsson，等;《International Journal of Cancer》;20080916;第124卷(第6期);第1463页摘要、第1467页右栏第3段 *
Symmetrical a-bromoacryloylamido diaryldienone derivatives as a novel series of antiproliferative agents. Design, synthesis and biological evaluation;Romeo Romagnoli，等;《Bioorganic & Medicinal Chemistry Letters》;20100325;第20卷(第9期);第2733页摘要、第2734页图1 *
泛素化/去泛素化系统的生物化学和生物学功能;李杨，等;《生命的化学》;20061231;第26卷(第6期);第515-517页 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023236583A1 (zh) * 2022-06-07 2023-12-14 北京大学 Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用

Also Published As

Publication number Publication date
KR102022575B1 (ko) 2019-09-18
WO2013058691A1 (en) 2013-04-25
ES2713484T3 (es) 2019-05-22
AU2012326682A1 (en) 2014-05-01
US20140228354A1 (en) 2014-08-14
EP2780326B1 (en) 2018-12-26
DK2780326T3 (en) 2019-03-04
MX345467B (es) 2017-02-01
MX2014004646A (es) 2014-08-01
KR20140078742A (ko) 2014-06-25
AU2012326682B2 (en) 2016-02-18
ZA201403302B (en) 2015-05-27
PT2780326T (pt) 2019-03-04
HUE041816T2 (hu) 2019-05-28
EP2780326A1 (en) 2014-09-24
MY169330A (en) 2019-03-21
US9221761B2 (en) 2015-12-29
IL232118A (en) 2016-06-30
CA2852518A1 (en) 2013-04-25
SG11201401608PA (en) 2014-07-30
BR112014009365B1 (pt) 2021-08-03
CN104271557A (zh) 2015-01-07
EA201490800A1 (ru) 2014-09-30
EA026409B1 (ru) 2017-04-28
BR112014009365A2 (pt) 2017-04-18
CL2014000998A1 (es) 2014-10-10
HK1203194A1 (en) 2015-10-23
NZ624019A (en) 2016-07-29
JP2014530852A (ja) 2014-11-20
CA2852518C (en) 2019-09-24
JP6165748B2 (ja) 2017-07-19
PL2780326T3 (pl) 2019-06-28
EP2780326A4 (en) 2015-04-22
IL232118A0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
CN104271557B (zh) 去泛素化活性的抑制方法
CN113164495B (zh) E3连接酶的共价靶向
Huang et al. Drugging the undruggables: exploring the ubiquitin system for drug development
Li et al. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug
Blackburn et al. Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform
CN115996716A (zh) Eif4a抑制剂组合
MX2008011837A (es) Compuestos de union al dominio de repeticion de inhibidores de proteinas de apoptosis de baculovirus.
US9896420B2 (en) N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
JP2000517319A (ja) システインプロテアーゼのインヒビター
Hu et al. A review of the known MTA-cooperative PRMT5 inhibitors
Blaquiere et al. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases
Xiong et al. Development of potent NEDD8-activating enzyme inhibitors bearing a pyrimidotriazole scaffold
Zhao et al. From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology
Tasneem et al. Heterocyclic moieties as HDAC inhibitors: role in cancer therapeutics
Groll et al. A minimal β‐lactone fragment for selective β5c or β5i proteasome inhibitors
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
US20130079370A1 (en) Method for the Inhibition of Deubiquitinating Activity
Liu et al. HSP90 Mediates Targeted Degradation of Nonclient Protein PARP1 for Breast Cancer Treatment
US20250282783A1 (en) Protein stabilizing compounds containing usp28 and/or usp25 targeting ligands
HK1203194B (en) Method for inhibition of deubiquitinating activity
CA3224123A1 (en) Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
SE1200735A1 (sv) Sätt att inhibera deubiqutineringsaktivitet
JP2008517065A (ja) Ｂｒｃａ２−ｒａｄ５１相互作用の破壊のための組成物及び方法
Ma et al. Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity
CN114920728B (zh) 一种甲异靛衍生物及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203194

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1203194

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171205